Trade Ipsen - IPN CFD

161.37-0.65%
The chart shows the IPN stock price data over the last 1 day, with a current price of 161.37, a high of 161.43, and a low of 159.73.
Low: 159.73High: 161.43
Sellers:
50%
Buyers:
50%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial instrument is available for trading through CFDs and Knock-outs.

Knock-out options available only for selected countries.
Learn more about:CFDsKnock-outs
Spread0.64
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
€1,000.00
Overnight funding adjustment
Charges from full value of position
-0.017296 %
(-€0.86)

Trade size with leverage ~ €5,000.00

Money from leverage ~€4,000.00


-0.01730%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
€1,000.00
Overnight funding adjustment
Charges from full value of position
-0.004926 %
(-€0.25)

Trade size with leverage ~ €5,000.00

Money from leverage ~€4,000.00


-0.00493%
Overnight funding adjustment time21:00 (UTC)
CurrencyEUR
Min traded quantity0.1
Margin20.00%
Stock exchangeFrance
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close162.13
Open161.43
1-Year Change58.13%
Day's Range159.73 - 161.43

Trade Ipsen - IPN CFD

Founded in 1929, Ipsen (IPN) is a leading international biopharmaceutical group, focusing on specialty care. The company develops and produces innovative medicines in 3 major areas: rare diseases, neurosciences and oncology. Ipsen also runs a consumer healthcare business. In general, the company sells over 20 drugs in more than 115 countries worldwide. Ipsen's R&D is focused on its differentiated and innovative technological platforms in the leading biotechnological hubs, based in Cambridge, the US, Oxford, the UK, and Paris-Saclay, France. Headquartered in Paris, the company employs 5,100 specialists. Included to the CAC Mid 60 index, the Ipsen share price (IPN) is set and traded on the Euronext Paris exchange.

Latest shares articles

Eni stock forecast: Buyback and Searah JV
Eni is an Italian energy company listed on the Borsa Italiana, with recent focus on its €2.8bn buyback and Searah joint venture with Petronas. Explore third-party ENI price targets and technical analysis. Past performance is not a reliable indicator of future results.
22 hours ago
BPER Banca stock forecast: Sondrio merger integration
BPER Banca is an Italian banking group listed in Milan, with recent results reflecting the completed €5.4bn integration of Banca Popolare di Sondrio. Explore third-party BPE price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:24, 23 June 2026
Assicurazioni Generali stock forecast: Moody’s upgrade, UniCredit stake
Assicurazioni Generali is an Italian insurer whose 2026 share performance follows a Moody’s rating upgrade and UniCredit’s disclosed 8.72% stake. Explore third-party G price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:39, 16 June 2026
Intesa Sanpaolo stock forecast: MPS offer in focus
Intesa Sanpaolo is an Italian banking group in focus after its €30.60bn MPS offer, launched amid ECB rate moves and wider European bank consolidation. Explore third-party ISP price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:30, 16 June 2026
Related News
Public TechnologiesEurope
12:15 (UTC), 24 June 2026
Merck KGaA names Miguel Fernández Alcalde head of global commercial strategy
Public TechnologiesEurope
13:05 (UTC), 23 June 2026
Ipsen says BlackRock lifts beneficial stake to 5.09% of capital
Public TechnologiesEurope
16:00 (UTC), 22 June 2026
Ipsen buys back own stock worth EUR 4.39 million under MAR Article 5 program
GlobeNewswireEurope
16:00 (UTC), 22 June 2026
Buy-back programme - Art 5 of MAR - Week 25 - 2026
GlobeNewswireEurope
16:10 (UTC), 15 June 2026
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
GlobeNewswireEurope
16:10 (UTC), 15 June 2026
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
GlobeNewswireEurope
16:00 (UTC), 15 June 2026
Buy-back programme - Art 5 of MAR - Week 24 - 2026
Public TechnologiesEurope
13:51 (UTC), 11 June 2026
Ipsen says BlackRock beneficial ownership slips to 4.69% stake

User feedback and ratings

Read the feedback from our clients1, whatever their experience level.
2025-07-01
P**** R******

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-22
J*** A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-22
D******

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-16
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Three steps to get started

1. Create your account (subject to eligibility)2. Deposit on your terms3. Trade when you’re ready